 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
51 News |  |
- PSB202 / Sound Biologics
Development of PSB202, a bifunctional antibody pair that target CD20 and CD37, for the treatment of B-cell malignancies (Section 38) - Mar 9, 2022 - Abstract #AACR2022AACR_4832;
P1a/1b
Systemic depletion of normal and malignant B-cells by anti-CD20 antibodies (e.g. rituximab and obinutuzumab) and anti-CD37 antibodies (e.g. otlertuzumab and BI 836826) has been well tolerated in clinical studies...Synergy was demonstrated for PSB202 in combination with lenalidomide...PSB202 offers the potential to improve clinical efficacy, decrease drug resistance, provide administration convenience especially when combining with additional therapeutics, lower the cost for treatment, and reduce the unwanted side effects from chemotherapy. PSB202 is currently being evaluated in patients with previously treated, relapsed, indolent B-cell malignancies (NCT05003141).
- || BI 836826 / Boehringer Ingelheim
Clinical, Journal, Combination therapy: A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. (Pubmed Central) - Feb 3, 2022
P2
Overall objective response rate was 38%, including two patients (10%) with complete remission and six patients (29%) with partial remission. Conclusions BI 836826 in combination with GemOx was generally well tolerated but did not exceed the MTD at doses up to 100 mg given every 14 days.
- || BI 836826 / Boehringer Ingelheim
Clinical, Journal, Combination therapy: A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. (Pubmed Central) - Feb 3, 2022
BI 836826 + ibrutinib did not exceed the MTD at doses up to 200 mg in patients with CLL. However, RP2D and MTD were not formally established, as the sponsor discontinued the trial.
- || BI 836826 / Boehringer Ingelheim
Clinical, P1 data, Journal: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. (Pubmed Central) - Sep 4, 2021
P1
BI 836826 demonstrated preliminary activity; the most frequent adverse events were hematotoxicity and infusion-related reactions which were manageable after amending the infusion schedule. Although BI 856826 will not undergo further clinical development, these results confirm CD37 as a valid therapeutic target in B cell NHL.
- | BI 836826 / Boehringer Ingelheim
P1 data, Journal: Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. (Pubmed Central) - Feb 7, 2020
Although BI 856826 will not undergo further clinical development, these results confirm CD37 as a valid therapeutic target in B cell NHL. No abstract available
- | BI 836826 / Boehringer Ingelheim
Trial completion, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - Jul 15, 2019
P1, N=7, Completed, Sponsor: Boehringer Ingelheim
No abstract available Active, not recruiting --> Completed
- | BI 836826 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - Jul 1, 2019
P1, N=7, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial completion date: Nov 2019 --> Jul 2019 | Trial primary completion date: Oct 2019 --> Jun 2019
- | BI 836826 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - Jun 25, 2018
P1, N=7, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2019 --> Jul 2019 | Trial primary completion date: Oct 2019 --> Jun 2019 Trial completion date: Nov 2022 --> Nov 2019 | Trial primary completion date: Aug 2020 --> Oct 2019
- BI 836826 / Boehringer Ingelheim
Enrollment closed, Enrollment change, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - Apr 9, 2018
P1, N=7, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2022 --> Nov 2019 | Trial primary completion date: Aug 2020 --> Oct 2019 Recruiting --> Active, not recruiting | N=60 --> 7
- | BI 836826 / Boehringer Ingelheim
Trial completion, Trial completion date: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Mar 8, 2018
P1, N=48, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=60 --> 7 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018
- | BI 836826 / Boehringer Ingelheim
Enrollment closed, Enrollment change, Combination therapy: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov) - Mar 2, 2018
P2, N=21, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 Recruiting --> Active, not recruiting | N=153 --> 21
- || BI 836826 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov) - Feb 23, 2018
P2, N=153, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=153 --> 21 Trial primary completion date: Nov 2019 --> Jun 2018 | Trial completion date: Nov 2019 --> Jun 2018
- BI 836826 / Boehringer Ingelheim
Enrollment change, Trial withdrawal, Combination therapy: This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax (clinicaltrials.gov) - Jan 9, 2018
P1, N=0, Withdrawn, Sponsor: Boehringer Ingelheim
Trial primary completion date: Nov 2019 --> Jun 2018 | Trial completion date: Nov 2019 --> Jun 2018 N=40 --> 0 | Not yet recruiting --> Withdrawn
- BI 836826 / Boehringer Ingelheim
Enrollment closed: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Dec 27, 2017
P1, N=48, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=40 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | BI 836826 / Boehringer Ingelheim
New P1 trial, Combination therapy: This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax (clinicaltrials.gov) - Nov 17, 2017
P1, N=40, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - Oct 4, 2017
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2019 --> Aug 2020
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - Aug 2, 2017
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jun 2019 --> Aug 2020 Trial primary completion date: Aug 2018 --> Jun 2019
- Zydelig (idelalisib) / Gilead
Trial termination, Trial primary completion date, Combination therapy: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 1, 2017
P1b/2, N=2, Terminated, Sponsor: Gilead Sciences
Trial primary completion date: Aug 2018 --> Jun 2019 Active, not recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2017
- ||| BI 836826 / Boehringer Ingelheim
Enrollment open, Trial primary completion date: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Jul 21, 2017
P1, N=53, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jul 2017 Suspended --> Recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- | BI 836826 / Boehringer Ingelheim
Trial completion, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Jul 19, 2017
P1, N=37, Completed, Sponsor: Boehringer Ingelheim
Suspended --> Recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed
- BI 836826 / Boehringer Ingelheim
Trial primary completion date, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Jun 23, 2017
P1, N=37, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Jun 2017
- Zydelig (idelalisib) / Gilead
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 10, 2017
P1b/2, N=2, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jan 2017 --> Jun 2017 Recruiting --> Active, not recruiting | N=92 --> 2 | Trial primary completion date: Nov 2021 --> Jan 2018
- | BI 836826 / Boehringer Ingelheim
Trial suspension: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Apr 4, 2017
P1, N=53, Suspended, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=92 --> 2 | Trial primary completion date: Nov 2021 --> Jan 2018 Recruiting --> Suspended
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Jan 23, 2017
P1, N=53, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Trial primary completion date: Jan 2017 --> Jun 2017
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date, Combination therapy: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov) - Jan 5, 2017
P2, N=138, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jan 2017 --> Jun 2017 Trial primary completion date: Jun 2019 --> Nov 2019
- BI 836826 / Boehringer Ingelheim
Enrollment change, Trial primary completion date, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Oct 26, 2016
P1, N=37, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jun 2019 --> Nov 2019 N=60 --> 37 | Trial primary completion date: Oct 2016 --> Jan 2017
- || Zydelig (idelalisib) / Gilead
Phase classification, Trial primary completion date, Combination therapy: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 11, 2016
P1b/2, N=92, Recruiting, Sponsor: Gilead Sciences
N=60 --> 37 | Trial primary completion date: Oct 2016 --> Jan 2017 Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jan 2020 --> Nov 2021
- || BI 836826 / Boehringer Ingelheim
Enrollment closed, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Aug 10, 2016
P1, N=60, Active, not recruiting, Sponsor: Boehringer Ingelheim
Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jan 2020 --> Nov 2021 Recruiting --> Active, not recruiting
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Jun 28, 2016
P1, N=53, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Jan 2017
- ||| BI 836826 / Boehringer Ingelheim
Enrollment open, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - Jun 28, 2016
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Sep 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- ||| BI 836826 / Boehringer Ingelheim
New P1 trial, Combination therapy: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib (clinicaltrials.gov) - May 3, 2016
P1, N=60, Not yet recruiting, Sponsor: Boehringer Ingelheim
- |||| BI 836826 / Boehringer Ingelheim
Enrollment open, Combination therapy: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov) - Apr 27, 2016
P2, N=138, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| BI 836826 / Boehringer Ingelheim
Enrollment closed, Combination therapy: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov) - Mar 23, 2016
P2, N=138, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| BI 836826 / Boehringer Ingelheim
Enrollment open, Combination therapy: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov) - Dec 29, 2015
P2, N=138, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| BI 836826 / Boehringer Ingelheim
New P2 trial, Combination therapy: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (clinicaltrials.gov) - Dec 9, 2015
P2, N=138, Not yet recruiting, Sponsor: Boehringer Ingelheim
- |||| Zydelig (idelalisib) / Gilead
Enrollment open, Combination therapy: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 25, 2015
P1/2, N=92, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Zydelig (idelalisib) / Gilead
Trial primary completion date, Combination therapy: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=92, Not yet recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2021 --> Jan 2020
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Aug 2021 --> Jan 2020 Trial primary completion date: Apr 2016 --> Oct 2016
- || BI 836826 / Boehringer Ingelheim
Enrollment change, Trial primary completion date: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Oct 22, 2015
P1, N=53, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Apr 2016 --> Oct 2016 N=77 --> 53 | Trial primary completion date: Apr 2016 --> Jul 2016
- ||||| Zydelig (idelalisib) / Gilead
New P1/2 trial, Combination therapy: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 2, 2015
P1/2, N=92, Not yet recruiting, Sponsor: Gilead Sciences
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Apr 14, 2015
P1, N=77, Recruiting, Sponsor: Boehringer Ingelheim
N=77 --> 53 | Trial primary completion date: Apr 2016 --> Jul 2016 Trial primary completion date: Oct 2015 --> Apr 2016
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Feb 23, 2015
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Nov 2015 --> Apr 2016
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Nov 6, 2014
P1, N=77, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: Nov 2014 --> Oct 2015
- || BI 836826 / Boehringer Ingelheim
Trial primary completion date, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Aug 7, 2014
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Nov 2014 --> Oct 2015 Trial primary completion date: Mar 2015 --> Nov 2015
- || BI 836826 / Boehringer Ingelheim
Enrollment change, Metastases: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (clinicaltrials.gov) - Aug 28, 2013
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Mar 2015 --> Nov 2015 N=50 --> 60
- || BI 836826 / Boehringer Ingelheim
Enrollment change: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Apr 16, 2013
P1, N=70, Recruiting, Sponsor: Boehringer Ingelheim
N=50 --> 60 N=50 --> 70
- ||| BI 836826 / Boehringer Ingelheim
Enrollment open: BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov) - Aug 22, 2011
P1, N=70, Recruiting, Sponsor: Boehringer Ingelheim
N=50 --> 70 Not yet recruiting --> Recruiting